Allianz Asset Management’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-57,540
| Closed | -$3.9M | – | 2920 |
|
|
2019
Q3 | $3.9M | Sell |
57,540
-34,141
| -37% | -$2.34M | ﹤0.01% | 1566 |
|
|
2019
Q2 | $5.33M | Buy |
91,681
+6,254
| +7% | +$370K | 0.01% | 1473 |
|
|
2019
Q1 | $5.98M | Buy |
85,427
+24,802
| +41% | +$1.84M | 0.01% | 1372 |
|
|
2018
Q4 | $3.9M | Sell |
60,625
-13,295
| -18% | -$932K | ﹤0.01% | 1502 |
|
|
2018
Q3 | $5.19M | Sell |
73,920
-920
| -1% | -$53.8K | ﹤0.01% | 1544 |
|
|
2018
Q2 | $3.77M | Sell |
74,840
-2,675
| -3% | -$106K | ﹤0.01% | 1658 |
|
|
2018
Q1 | $2.42M | Buy |
77,515
+1,840
| +2% | +$61K | ﹤0.01% | 1837 |
|
|
2017
Q4 | $2.59M | Buy |
+75,675
| New | +$2.41M | ﹤0.01% | 1920 |
|
|
2016
Q4 | – | Sell |
-19,540
| Closed | -$565K | – | 2717 |
|
|
2016
Q3 | $565K | Sell |
19,540
-5,020
| -20% | -$140K | ﹤0.01% | 2340 |
|
|
2016
Q2 | $636K | Buy |
24,560
+10,160
| +71% | +$270K | ﹤0.01% | 2256 |
|
|
2016
Q1 | $357K | Buy |
+14,400
| New | +$395K | ﹤0.01% | 2317 |
|
|
2013
Q3 | – | Sell |
-29,200
| Closed | -$926K | – | 1864 |
|
|
2013
Q2 | $926K | Buy |
+29,200
| New | +$959K | ﹤0.01% | 1367 |
|
Allianz Asset Management's GHDX Position: Q4 2019 in Review
Allianz Asset Management sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 57,540 shares — an estimated $3.9M sold.
Allianz Asset Management first reported a position in GHDX in Q2 2013 and held it in 12 quarters. The position peaked at $5.98M in Q1 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Allianz Asset Management reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Allianz Asset Management sold 57,540 Genomic Health, Inc. shares in Q4 2019, an estimated $3.9M.
- Allianz Asset Management first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 12 quarters.
- Allianz Asset Management's Genomic Health, Inc. position peaked at $5.98M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Allianz Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.